Vertex Pharmaceuticals (VRTX): Q1 2026 Earnings Highlight CF Strength and Non-CF Progress
Key Takeaways
- Vertex reported Q1 2026 total revenue of $2.99 billion, up 8% year-over-year from $2.77 billion, driven by cystic fibrosis (CF) franchise strength.
- Non-GAAP diluted EPS (earnings per share) came in at $4.47, surpassing consensus estimates around $4.23-$4.43; GAAP EPS was $4.02.
- CF products generated $2.92 billion, with TRIKAFTA/KAFTRIO at $2.35 billion and new entrant ALYFTREK at $424 million.
- Non-CF products CASGEVY and JOURNAVX contributed $72 million combined, accounting for over 25% of revenue growth.
- Company reiterated full-year 2026 revenue guidance of $12.95-$13.1 billion, including at least $500 million from non-CF products.
- Cash position stood at $13.0 billion, supporting ongoing share repurchases and pipeline investments.
Understanding Vertex's Q1 Results and Their Implications
I've been following Vertex Pharmaceuticals (VRTX) closely as a leader in cystic fibrosis treatments, and their Q1 2026 results, released on May 4 for the period ended March 31, provide a clear snapshot. This quarter matters because it shows how well the mature CF franchise is holding up while newer therapies in sickle cell disease, beta thalassemia, and acute pain gain traction. In a biotech environment facing pricing pressures and pipeline uncertainties, Vertex's ability to diversify stands out. The strong demand for CF products and initial non-CF contributions demonstrate resilience, and the reaffirmed guidance gives me confidence they can meet annual targets even with headwinds like potential tariffs.
Breaking Down the Numbers
Vertex posted total revenues of $2.99 billion for Q1 2026, marking an 8% rise from $2.77 billion in Q1 2025. This came in slightly below some expectations near $3.0 billion but matched Zacks estimates closely. U.S. revenues increased 7% to $1.78 billion, while ex-U.S. grew 9% to $1.21 billion, supported by CF uptake and favorable foreign exchange.
The CF portfolio remained the core driver, delivering $2.92 billion in sales: TRIKAFTA/KAFTRIO at $2.35 billion, ALYFTREK at $424 million (with cumulative sales over $1 billion since launch), and other CF products at $136 million. The newer products performed well too, with CASGEVY (for sickle cell disease and transfusion-dependent beta thalassemia, or TDT) at $43 million and JOURNAVX (acute pain) at $29 million, together accounting for more than 25% of the growth.
Non-GAAP diluted EPS hit $4.47, exceeding Zacks consensus of $4.23 by 5.76% and last year's $4.06; GAAP EPS was $4.02, up from $2.49. The non-GAAP operating margin reached 44%. Vertex also reiterated its 2026 guidance: total revenue of $12.95-$13.1 billion; non-GAAP R&D, acquired IPR&D, and SG&A expenses of $5.65-$5.75 billion; and a non-GAAP tax rate of 19.5%-20.5%.
Market Response and What Investors Are Thinking
After the earnings release, VRTX shares closed up 1.40% at $429.85 on May 4, with mixed after-hours moves—some reports showed a slight 0.1% gain to $424.02, while others noted a 1.14% dip. The EPS beat was positive, but revenue that was in line or slightly soft against higher hopes tempered the reaction. Overall sentiment stays constructive due to the reliability of CF and pipeline momentum, even as investors digest the measured commentary on non-CF ramp-up. Analyst consensus remains overweight, with price targets around $548 signaling long-term optimism.
Looking Ahead: Guidance and Catalysts to Watch
From what I see, Vertex's reiterated 2026 guidance reflects steady execution. CF therapies like ALYFTREK and TRIKAFTA are now eligible for about 95% of U.S. CF patients after label expansions. One thing to monitor is the regulatory submissions for pediatric indications—ages 2-5 for ALYFTREK and 1-<2 for TRIKAFTA—planned for H1 2026.
Non-CF progress is particularly important: CASGEVY's U.S. filing for ages 5-<12 is under priority review, and a Germany pricing deal could boost adoption; JOURNAVX aims for 3x prescription growth with new Medicare and Medicaid coverage reaching millions more lives. Key metrics include over 500 CASGEVY initiations and 1 million JOURNAVX prescriptions to date, pointing to real scaling potential.
The pipeline holds significant catalysts. Povetacicept's BLA for IgA nephropathy (IgAN) seeks accelerated approval after positive Phase 3 data, with Phase 3 advancing in primary membranous nephropathy. CF next-gen VX-828 dosing wraps up in H1 2026, with readout in H2; pain programs like suzetrigine wrap enrollment by year-end. Inaxaplin's Phase 3 interim is eyed for early 2027.
With a $13 billion cash position, Vertex can fund R&D (including about $100 million in acquired IPR&D) and share repurchases, even as tariff impacts remain minor. I’m watching CF pricing and demand, non-CF uptake, and regulatory milestones closely for signs of successful diversification.
Leveraging Tickeron's AI Screener in My Analysis
In reviewing VRTX, I also checked this using Tickeron’s AI Screener to see how the stock stacks up against biotech peers on fundamentals and trends. This AI-powered tool scans thousands of stocks and ETFs with customizable filters for technical patterns, volatility, and performance metrics, helping pinpoint opportunities efficiently. It's become part of my routine for deeper context beyond earnings—worth exploring if you're building your own watchlist.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
VRTX's Stochastic Oscillator is remaining in oversold zone for 2 days
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +1.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRTX advanced for three days, in 241 of 367 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.
VRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VRTX as a result. In 41 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 47%.
The Moving Average Convergence Divergence Histogram (MACD) for VRTX turned negative on October 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 59 similar instances when the indicator turned negative. In 29 of the 59 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.
VRTX moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VRTX crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 47%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.
The Aroon Indicator for VRTX entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 19 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 41 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. VRTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.605) is normal, around the industry mean (26.780). P/E Ratio (30.732) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (1.939) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (10.449) is also within normal values, averaging (438.009).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company that discovers and develops novel, small molecule pharmaceuticals
Industry Biotechnology
Advertisement